Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study.
about
Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritisEvidence for early disease-modifying drugs in rheumatoid arthritisChronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a reviewComparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritisRadiological damage in patients with rheumatoid arthritis on sustained remission.Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold valuesExpression of VSTM1-v2 Is Increased in Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis and Is Correlated with Disease Activity.Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?Treating very early rheumatoid arthritisCombination therapy for rheumatoid arthritis in the era of biologicalsReductions in radiographic progression in early RA over 25-years: Changing contribution from RF in 2 multi-centre UK inception cohorts.Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathwayExpression of G protein αq Subunit is Decreased in Lymphocytes from Patients with Rheumatoid Arthritis and is Correlated with Disease Activity.Reduced Activity of HDAC3 and Increased Acetylation of Histones H3 in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis
P2860
Q24235784-7BFED751-5F38-4C8A-AEDA-EF3BF3D9B483Q24793240-55CC2ECD-B887-4471-B9C4-D4215C1F9EEBQ28079074-BCE79D2E-EB96-42AD-B9DB-99FDA459B639Q35638194-5F1B3EA1-7F76-46F3-8481-C1100D35FE9EQ35759974-69C5DC2B-5572-4DF4-A956-05E63F0AEA7CQ35760044-60A2E967-8B37-43B0-A098-2785A42BABC9Q35892485-BF221C67-6707-43D1-BF65-BA68B17E3F67Q36204088-B32C3A97-5C1A-41C7-BF2C-33A4A5E25748Q36486374-1546095A-BF3A-473B-B88E-DC18BBA125C6Q36596130-5EA5CAD8-D409-4850-8548-DC2B56CC36C1Q36823684-13766336-8690-420B-9301-400AD2796BA3Q38952206-5D9F9909-3F60-4FBF-A201-BEF67E475F35Q39924118-C5CBB9E7-449D-4BBB-BF27-5EC3EBF4CEE2Q54559778-C0498283-2F9F-4536-A727-9E84039F6E0DQ58585469-ECF0AD92-44D9-4767-BE19-3F578C1B7F21
P2860
Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Long term structural effects o ...... double blind controlled study.
@ast
Long term structural effects o ...... double blind controlled study.
@en
type
label
Long term structural effects o ...... double blind controlled study.
@ast
Long term structural effects o ...... double blind controlled study.
@en
prefLabel
Long term structural effects o ...... double blind controlled study.
@ast
Long term structural effects o ...... double blind controlled study.
@en
P2093
P356
P1476
Long term structural effects o ...... double blind controlled study.
@en
P2093
A Cantagrel
J F Maillefert
M Dougados
P Goupille
P304
P356
10.1136/ARD.62.8.764
P407
P577
2003-08-01T00:00:00Z